Virtual Symposium: Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis
The increasing incidence of Atopic dermatitis (AD) and poor recognition of the disease in some patient groups is a public health concern. AD symptoms and its daily management cause significant effects on quality of life for both patients and caregivers. AD is associated with an increase in other atopic manifestations as well as with serious comorbidities that can greatly affect overall patient health and wellbeing (Silverberg 2015; Simpson 2012; Yu 2016; Zheng 2011). Timely and adequate treatment of AD is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions (Leung 2014). However, the treatment of AD is a clinical challenge. Patients continue to report treatment dissatisfaction, recurrent flares, and impaired quality of life (Silverberg 2018; Wei 2019). Targeted immunomodulatory agents, based on recent advances in the understanding of AD pathophysiology, represent additional options for long-term control, with one agent that is FDA approved and several others in advanced clinical development (Kalamaha 2019). Thus, additional education about current and emerging long-term strategies to AD management is crucial for their interpretation and application to clinical practice.
This symposium is designed for an audience of physicians, nurses and professional staff members of medical practices specializing in dermatology as well as allergists, primary care physician, nurses, nurse practitioners, physician assistants and pharmacists.
- Interpret the efficacy and safety of current non-pharmacological and pharmacological treatments for AD and their limitations in long-term disease management
- Summarize the mechanisms of action and evidence with new and emerging targeted immunomodulatory agents for long-term AD management
- Develop individualized treatment plans for patients with moderate-to-severe AD that go beyond just treating flares and symptoms in order to optimize long-term control and overall quality of life
Linda Stein Gold is Director of Dermatology Clinical Research for the Henry Ford Health System in Detroit, Michigan. She is also Division Head of Dermatology for the Henry Ford Health System in West Bloomfield, Michigan. She received her medical degree from University of Pennsylvania School of Medicine in Philadelphia, completed an internship in the Department of Internal Medicine at the Hospital of the University of Pennsylvania in Philadelphia, and was Chief Resident in the Department of Dermatology at Henry Ford Hospital in Detroit.
Dr. Stein Gold has just been elected to the office of Vice President of the American Academy of Dermatology. She will take office as Vice President-Elect at the conclusion of the 2021 Annual Meeting in San Francisco, CA on March 23, 2021. Dr. Stein Gold has just completed her service on the Board of Directors of the American Academy of Dermatology and the Executive, Priorities, Corporate Relations, and Budget Committees. She has authored more than 75 articles published in journals including Journal of the American Academy of Dermatology, Journal of Dermatological Treatment, Pediatric Dermatology, Journal of Clinical and Aesthetic Dermatology, and Seminars in Cutaneous Medicine and Surgery.
Dr. Stein Gold is a frequent national and international lecturer on the areas of psoriasis, alopecia, viral infections, atopic dermatitis, and fungal infections. Her recent research has focused on treatments for papulopustular rosacea, acne vulgaris, plaque-type psoriasis, atopic dermatitis, and alopecia areata.
Andrew F. Alexis, MD, MPH is the Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. He is also Professor of Dermatology at the Icahn School of Medicine at Mount Sinai. As Director of the Skin of Color Center, he is actively involved in advancing patient care, research, and education pertaining to dermatologic disorders that are prevalent in ethnic skin.
Dr. Alexis received his medical degree from Columbia University College of Physicians & Surgeons and his Master of Public Health at Columbia University’s Mailman School of Public Health. He completed his dermatology residency at Weill Cornell Medical Center, followed by a fellowship in dermatopharmacology at New York University School of Medicine.
Dr. Alexis has published more than 80 articles in peer-reviewed journals including the British Journal of Dermatology, Journal of the American Academy of Dermatology, and JAMA Dermatology among others. He has co-edited two text books on dermatology for skin of color - Skin of Color A Practical Guide to Dermatologic Diagnosis and Treatment (Springer Publishing 2013) and Ethnic Dermatology: Principles and Practice (Wiley-Blackwell 2013) – and authored 10 book chapters.
Dr. Alexis has held numerous leadership positions in professional organizations including Past President of the New York Academy of Medicine Dermatology Section, Secretary/Treasurer of the Skin of Color Society and Chair of the Diversity Task Force Committee for the American Academy of Dermatology. He currently serves as President of the New York Dermatological Society, Chair of the Scientific Committee of the Skin of Color Society, and is a member of the Board of Directors of the Cicatricial Alopecia Research Foundation.
Dr. Alexis has appeared on ABC, CBS, NBC, and FOX television news programs and has been quoted in numerous leading publications, including the New York Times, Wall Street Journal, Forbes, Allure, and Essence. He is listed in Castle Connolly’s Top Doctors ™ and Super Doctors®.
Peter Lio, MD is a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine. Dr. Lio received his medical degree from Harvard Medical School, completed his internship in Pediatrics at Boston Children’s Hospital, and his Dermatology training at Harvard where he served as Chief Resident in Dermatology. While at Harvard, he received formal training in acupuncture. Dr. Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He currently serves as a board member and scientific advisory committee member for the National Eczema Association. He is a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group and a founding faculty member of the Integrative Dermatology Certificate Program. He has over 150 publications and 2 textbooks.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity hs been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
1 ANCC contact hours
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
This activity is supported by educational grants from Incyte Corporation, Pfizer Inc.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Andrew Alexis, MD
Leo, Novartis, Menlo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Unilever, Beiersdorf, Valeant, L’Oreal, BMS, Menlo, Scientis, Bausch health, UCB, Foamix , Cassiopea, Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel (Self); Pfizer, Sanofi-Regeneron (Spouse/partner)
Leo, Novartis, Almirall, Bristol-Myers-Squibb, Celgene, Menlo, Galderma, Valeant (Bausch Health), Cara, Arcutis
Peter Lio, MD
UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, Eli Lilly, Micreos, L'Oreal, Pierre-Fabre, Johnson & Johnson, Level Ex, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs, Galderma, Verrica, Arbonne, Amyris, Bodewell, Burt's Bees, Kimberly-Clark
National Eczema Association, AOBiome, Regeneron/Sanofi Genzyme, and AbbVie
Theraplex: Theraplex AIM OTC moisturizer
Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, Galderma, L'Oreal
Micreos Altus Labs
Linda Stein Gold, MD
Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall, BMS, UCB, Sol Gel, Ortho Derm
Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Almirall, UCB, Sol Gel, Ortho Derm, Novartis, AbbVie
Galderma, Sun, Pfizer, Amgen, Sanofi, Regeneron, Vyne Therapeutics Inc, Ortho Derm
Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations
Nothing to disclose
LiVDerm Planners and Reviewers
Nothing to disclose
AKH Planners and Reviewers
Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
- 1.00 AAPA Category I CME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.